The potential therapeutic applications of CRISPR/Cas9 in colorectal cancer

Toktam Sahranavard; Shima Mehrabadi; Ghazaleh Pourali; Mina Maftooh; Hamed Akbarzade; Seyed Mahdi Hassanian; Majid Ghayour Mobarhan; Gordon A Ferns; Majid Khazaei; Amir Avan

doi:10.2174/0929867331666230915103707

The potential therapeutic applications of CRISPR/Cas9 in colorectal cancer

Curr Med Chem. 2023 Sep 15. doi: 10.2174/0929867331666230915103707. Online ahead of print.

Affiliations

¹ Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
² Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
³ Brighton and Sussex Medical School Division of Medical Education Brighton United Kingdom.

PMID: 37724673
DOI: 10.2174/0929867331666230915103707

Abstract

The application of the CRISPR-associated nuclease 9 (Cas9) system in tumor studies has led to the discovery of several new treatment strategies for colorectal cancer (CRC), including the recognition of novel target genes, the construction of animal mass models, and the identification of genes related to chemotherapy resistance. CRISPR/Cas9 can be applied to genome therapy for CRC, particularly regarding molecular-targeted medicines and suppressors. This review summarizes some aspects of using CRISPR/Cas9 in treating CRC. Further in-depth and systematic research is required to fully realize the potential of CRISPR/Cas9 in CRC treatment and integrate it into clinical practice.

Keywords: CRISPR/Cas9; clinical trial; colorectal cancer; treatmen.